A role for microfluidic systems in precision medicine
Abstract
Precision oncology continues to challenge the “one-size-fits-all” dogma. Under the precision oncology banner, cancer patients are screened for molecular tumor alterations that predict treatment response, ideally leading to optimal treatments. Functional assays that directly evaluate treatment efficacy on the patient’s cells offer an alternative and complementary tool to improve the accuracy of precision oncology. Unfortunately, traditional Petri dish-based assays overlook much tumor complexity, limiting their potential as predictive functional biomarkers. Here, we review past applications of microfluidic systems for precision medicine and discuss the present and potential future role of functional microfluidic assays as treatment predictors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 02, 2022
- Source ID
- 10.1038/s41467-022-30384-7
Entities
People
- David J Beebe
- Joshua M. Lang
- José M Ayuso
- María Virumbrales-Muñoz
Organizations
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense
- United States Department of Health and Human Services